Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
Abstract Aims REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment per...
Gespeichert in:
| Veröffentlicht in: | European heart journal 2022-04, Vol.43 (14), p.1416-1424 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1424 |
|---|---|
| container_issue | 14 |
| container_start_page | 1416 |
| container_title | European heart journal |
| container_volume | 43 |
| creator | Sammons, E Hopewell, J C Chen, F Stevens, W Wallendszus, K Valdes-Marquez, E Dayanandan, R Knott, C Murphy, K Wincott, E Baxter, A Goodenough, R Lay, M Hill, M Macdonnell, S Fabbri, G Lucci, D Fajardo-Moser, M Brenner, S Hao, D Zhang, H Liu, J Wuhan, B Mosegaard, S Herrington, W Wanner, C Angermann, C Ertl, G Maggioni, A Barter, P Mihaylova, B Mitchel, Y Blaustein, R Goto, S Tobert, J DeLucca, P Chen, Y Chen, Z Gray, A Haynes, R Armitage, J Baigent, C Wiviott, S Cannon, C Braunwald, E Collins, R Bowman, L Landray, M |
| description | Abstract
Aims
REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment period.
Methods and results
A total of 30 449 adults with prior atherosclerotic vascular disease were randomly allocated to anacetrapib 100 mg daily or matching placebo, in addition to open-label atorvastatin therapy. After stopping the randomly allocated treatment, 26 129 survivors entered a post-trial follow-up period, blind to their original treatment allocation. The primary outcome was first post-randomization major coronary event (i.e. coronary death, myocardial infarction, or coronary revascularization) during the in-trial and post-trial treatment periods, with analysis by intention-to-treat. Allocation to anacetrapib conferred a 9% [95% confidence interval (CI) 3–15%; P = 0.004] proportional reduction in the incidence of major coronary events during the study treatment period (median 4.1 years). During extended follow-up (median 2.2 years), there was a further 20% (95% CI 10–29%; P |
| doi_str_mv | 10.1093/eurheartj/ehab863 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8986460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehab863</oup_id><sourcerecordid>10.1093/eurheartj/ehab863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-e76e38a99fe8b7ec3545edcfefde661525ebd8decf958ed2e8e1f39025a47e443</originalsourceid><addsrcrecordid>eNqNUE1LAzEQDaLY-vEDvEh-gGuTZjdNLoIUv6DgRcGTy2x20k1pd5ckrfTfG6kWvXmZYZj33sx7hFxwds2ZFiNc-wbBx8UIG6iUFAdkyIvxONMyLw7JkHFdZFKqtwE5CWHBGFOSy2MyELnmjAs5JO-zrp1nEf2KBrAYtxTamqK1zoDZ0s6mGQxGD72rqGtpD9FhGwP9cLGhEBv0XTDLVKMzdAPBrJfgae0CQsAzcmRhGfD8u5-S1_u7l-ljNnt-eJrezjKTCxkznEgUCrS2qKoJGlHkBdbGoq1RymSpwKpWNRqrC4X1GBVyKzQbF5BPMM_FKbnZ6fbrapWY6UMPy7L3bgV-W3bgyr-b1jXlvNuUSiuZS5YE-E7AJDvBo91zOSu_wi73YZffYSfO5e-je8ZPuglwtQN06_4fep_gNpMh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Sammons, E ; Hopewell, J C ; Chen, F ; Stevens, W ; Wallendszus, K ; Valdes-Marquez, E ; Dayanandan, R ; Knott, C ; Murphy, K ; Wincott, E ; Baxter, A ; Goodenough, R ; Lay, M ; Hill, M ; Macdonnell, S ; Fabbri, G ; Lucci, D ; Fajardo-Moser, M ; Brenner, S ; Hao, D ; Zhang, H ; Liu, J ; Wuhan, B ; Mosegaard, S ; Herrington, W ; Wanner, C ; Angermann, C ; Ertl, G ; Maggioni, A ; Barter, P ; Mihaylova, B ; Mitchel, Y ; Blaustein, R ; Goto, S ; Tobert, J ; DeLucca, P ; Chen, Y ; Chen, Z ; Gray, A ; Haynes, R ; Armitage, J ; Baigent, C ; Wiviott, S ; Cannon, C ; Braunwald, E ; Collins, R ; Bowman, L ; Landray, M</creator><creatorcontrib>Sammons, E ; Hopewell, J C ; Chen, F ; Stevens, W ; Wallendszus, K ; Valdes-Marquez, E ; Dayanandan, R ; Knott, C ; Murphy, K ; Wincott, E ; Baxter, A ; Goodenough, R ; Lay, M ; Hill, M ; Macdonnell, S ; Fabbri, G ; Lucci, D ; Fajardo-Moser, M ; Brenner, S ; Hao, D ; Zhang, H ; Liu, J ; Wuhan, B ; Mosegaard, S ; Herrington, W ; Wanner, C ; Angermann, C ; Ertl, G ; Maggioni, A ; Barter, P ; Mihaylova, B ; Mitchel, Y ; Blaustein, R ; Goto, S ; Tobert, J ; DeLucca, P ; Chen, Y ; Chen, Z ; Gray, A ; Haynes, R ; Armitage, J ; Baigent, C ; Wiviott, S ; Cannon, C ; Braunwald, E ; Collins, R ; Bowman, L ; Landray, M ; HPS3/TIMI55-REVEAL Collaborative Group ; REVEAL Collaborative Group ; Writing Committee ; The HPS3/TIMI55-REVEAL Collaborative Group</creatorcontrib><description>Abstract
Aims
REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment period.
Methods and results
A total of 30 449 adults with prior atherosclerotic vascular disease were randomly allocated to anacetrapib 100 mg daily or matching placebo, in addition to open-label atorvastatin therapy. After stopping the randomly allocated treatment, 26 129 survivors entered a post-trial follow-up period, blind to their original treatment allocation. The primary outcome was first post-randomization major coronary event (i.e. coronary death, myocardial infarction, or coronary revascularization) during the in-trial and post-trial treatment periods, with analysis by intention-to-treat. Allocation to anacetrapib conferred a 9% [95% confidence interval (CI) 3–15%; P = 0.004] proportional reduction in the incidence of major coronary events during the study treatment period (median 4.1 years). During extended follow-up (median 2.2 years), there was a further 20% (95% CI 10–29%; P < 0.001) reduction. Overall, there was a 12% (95% CI 7–17%, P < 0.001) proportional reduction in major coronary events during the overall follow-up period (median 6.3 years), corresponding to a 1.8% (95% CI 1.0–2.6%) absolute reduction. There were no significant effects on non-vascular mortality, site-specific cancer, or other serious adverse events. Morbidity follow-up was obtained for 25 784 (99%) participants.
Conclusion
The beneficial effects of anacetrapib on major coronary events increased with longer follow-up, and no adverse effects emerged on non-vascular mortality or morbidity. These findings illustrate the importance of sufficiently long treatment and follow-up duration in randomized trials of lipid-modifying agents to assess their full benefits and potential harms.
Trial registration
International Standard Randomized Controlled Trial Number (ISRCTN) 48678192; ClinicalTrials.gov No. NCT01252953; EudraCT No. 2010-023467-18.
Structured Graphical Abstract
Structured Graphical Abstract</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehab863</identifier><identifier>PMID: 34910136</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Atherosclerosis - drug therapy ; Atorvastatin - therapeutic use ; Clinical Research ; Double-Blind Method ; Humans ; Myocardial Infarction - drug therapy ; Oxazolidinones - adverse effects ; Treatment Outcome</subject><ispartof>European heart journal, 2022-04, Vol.43 (14), p.1416-1424</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-e76e38a99fe8b7ec3545edcfefde661525ebd8decf958ed2e8e1f39025a47e443</citedby><cites>FETCH-LOGICAL-c436t-e76e38a99fe8b7ec3545edcfefde661525ebd8decf958ed2e8e1f39025a47e443</cites><orcidid>0000-0002-8647-0366 ; 0000-0001-6646-827X ; 0000-0001-8288-8602</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,1586,27933,27934</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34910136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sammons, E</creatorcontrib><creatorcontrib>Hopewell, J C</creatorcontrib><creatorcontrib>Chen, F</creatorcontrib><creatorcontrib>Stevens, W</creatorcontrib><creatorcontrib>Wallendszus, K</creatorcontrib><creatorcontrib>Valdes-Marquez, E</creatorcontrib><creatorcontrib>Dayanandan, R</creatorcontrib><creatorcontrib>Knott, C</creatorcontrib><creatorcontrib>Murphy, K</creatorcontrib><creatorcontrib>Wincott, E</creatorcontrib><creatorcontrib>Baxter, A</creatorcontrib><creatorcontrib>Goodenough, R</creatorcontrib><creatorcontrib>Lay, M</creatorcontrib><creatorcontrib>Hill, M</creatorcontrib><creatorcontrib>Macdonnell, S</creatorcontrib><creatorcontrib>Fabbri, G</creatorcontrib><creatorcontrib>Lucci, D</creatorcontrib><creatorcontrib>Fajardo-Moser, M</creatorcontrib><creatorcontrib>Brenner, S</creatorcontrib><creatorcontrib>Hao, D</creatorcontrib><creatorcontrib>Zhang, H</creatorcontrib><creatorcontrib>Liu, J</creatorcontrib><creatorcontrib>Wuhan, B</creatorcontrib><creatorcontrib>Mosegaard, S</creatorcontrib><creatorcontrib>Herrington, W</creatorcontrib><creatorcontrib>Wanner, C</creatorcontrib><creatorcontrib>Angermann, C</creatorcontrib><creatorcontrib>Ertl, G</creatorcontrib><creatorcontrib>Maggioni, A</creatorcontrib><creatorcontrib>Barter, P</creatorcontrib><creatorcontrib>Mihaylova, B</creatorcontrib><creatorcontrib>Mitchel, Y</creatorcontrib><creatorcontrib>Blaustein, R</creatorcontrib><creatorcontrib>Goto, S</creatorcontrib><creatorcontrib>Tobert, J</creatorcontrib><creatorcontrib>DeLucca, P</creatorcontrib><creatorcontrib>Chen, Y</creatorcontrib><creatorcontrib>Chen, Z</creatorcontrib><creatorcontrib>Gray, A</creatorcontrib><creatorcontrib>Haynes, R</creatorcontrib><creatorcontrib>Armitage, J</creatorcontrib><creatorcontrib>Baigent, C</creatorcontrib><creatorcontrib>Wiviott, S</creatorcontrib><creatorcontrib>Cannon, C</creatorcontrib><creatorcontrib>Braunwald, E</creatorcontrib><creatorcontrib>Collins, R</creatorcontrib><creatorcontrib>Bowman, L</creatorcontrib><creatorcontrib>Landray, M</creatorcontrib><creatorcontrib>HPS3/TIMI55-REVEAL Collaborative Group</creatorcontrib><creatorcontrib>REVEAL Collaborative Group</creatorcontrib><creatorcontrib>Writing Committee</creatorcontrib><creatorcontrib>The HPS3/TIMI55-REVEAL Collaborative Group</creatorcontrib><title>Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>Abstract
Aims
REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment period.
Methods and results
A total of 30 449 adults with prior atherosclerotic vascular disease were randomly allocated to anacetrapib 100 mg daily or matching placebo, in addition to open-label atorvastatin therapy. After stopping the randomly allocated treatment, 26 129 survivors entered a post-trial follow-up period, blind to their original treatment allocation. The primary outcome was first post-randomization major coronary event (i.e. coronary death, myocardial infarction, or coronary revascularization) during the in-trial and post-trial treatment periods, with analysis by intention-to-treat. Allocation to anacetrapib conferred a 9% [95% confidence interval (CI) 3–15%; P = 0.004] proportional reduction in the incidence of major coronary events during the study treatment period (median 4.1 years). During extended follow-up (median 2.2 years), there was a further 20% (95% CI 10–29%; P < 0.001) reduction. Overall, there was a 12% (95% CI 7–17%, P < 0.001) proportional reduction in major coronary events during the overall follow-up period (median 6.3 years), corresponding to a 1.8% (95% CI 1.0–2.6%) absolute reduction. There were no significant effects on non-vascular mortality, site-specific cancer, or other serious adverse events. Morbidity follow-up was obtained for 25 784 (99%) participants.
Conclusion
The beneficial effects of anacetrapib on major coronary events increased with longer follow-up, and no adverse effects emerged on non-vascular mortality or morbidity. These findings illustrate the importance of sufficiently long treatment and follow-up duration in randomized trials of lipid-modifying agents to assess their full benefits and potential harms.
Trial registration
International Standard Randomized Controlled Trial Number (ISRCTN) 48678192; ClinicalTrials.gov No. NCT01252953; EudraCT No. 2010-023467-18.
Structured Graphical Abstract
Structured Graphical Abstract</description><subject>Adult</subject><subject>Atherosclerosis - drug therapy</subject><subject>Atorvastatin - therapeutic use</subject><subject>Clinical Research</subject><subject>Double-Blind Method</subject><subject>Humans</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Oxazolidinones - adverse effects</subject><subject>Treatment Outcome</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqNUE1LAzEQDaLY-vEDvEh-gGuTZjdNLoIUv6DgRcGTy2x20k1pd5ckrfTfG6kWvXmZYZj33sx7hFxwds2ZFiNc-wbBx8UIG6iUFAdkyIvxONMyLw7JkHFdZFKqtwE5CWHBGFOSy2MyELnmjAs5JO-zrp1nEf2KBrAYtxTamqK1zoDZ0s6mGQxGD72rqGtpD9FhGwP9cLGhEBv0XTDLVKMzdAPBrJfgae0CQsAzcmRhGfD8u5-S1_u7l-ljNnt-eJrezjKTCxkznEgUCrS2qKoJGlHkBdbGoq1RymSpwKpWNRqrC4X1GBVyKzQbF5BPMM_FKbnZ6fbrapWY6UMPy7L3bgV-W3bgyr-b1jXlvNuUSiuZS5YE-E7AJDvBo91zOSu_wi73YZffYSfO5e-je8ZPuglwtQN06_4fep_gNpMh</recordid><startdate>20220406</startdate><enddate>20220406</enddate><creator>Sammons, E</creator><creator>Hopewell, J C</creator><creator>Chen, F</creator><creator>Stevens, W</creator><creator>Wallendszus, K</creator><creator>Valdes-Marquez, E</creator><creator>Dayanandan, R</creator><creator>Knott, C</creator><creator>Murphy, K</creator><creator>Wincott, E</creator><creator>Baxter, A</creator><creator>Goodenough, R</creator><creator>Lay, M</creator><creator>Hill, M</creator><creator>Macdonnell, S</creator><creator>Fabbri, G</creator><creator>Lucci, D</creator><creator>Fajardo-Moser, M</creator><creator>Brenner, S</creator><creator>Hao, D</creator><creator>Zhang, H</creator><creator>Liu, J</creator><creator>Wuhan, B</creator><creator>Mosegaard, S</creator><creator>Herrington, W</creator><creator>Wanner, C</creator><creator>Angermann, C</creator><creator>Ertl, G</creator><creator>Maggioni, A</creator><creator>Barter, P</creator><creator>Mihaylova, B</creator><creator>Mitchel, Y</creator><creator>Blaustein, R</creator><creator>Goto, S</creator><creator>Tobert, J</creator><creator>DeLucca, P</creator><creator>Chen, Y</creator><creator>Chen, Z</creator><creator>Gray, A</creator><creator>Haynes, R</creator><creator>Armitage, J</creator><creator>Baigent, C</creator><creator>Wiviott, S</creator><creator>Cannon, C</creator><creator>Braunwald, E</creator><creator>Collins, R</creator><creator>Bowman, L</creator><creator>Landray, M</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8647-0366</orcidid><orcidid>https://orcid.org/0000-0001-6646-827X</orcidid><orcidid>https://orcid.org/0000-0001-8288-8602</orcidid></search><sort><creationdate>20220406</creationdate><title>Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease</title><author>Sammons, E ; Hopewell, J C ; Chen, F ; Stevens, W ; Wallendszus, K ; Valdes-Marquez, E ; Dayanandan, R ; Knott, C ; Murphy, K ; Wincott, E ; Baxter, A ; Goodenough, R ; Lay, M ; Hill, M ; Macdonnell, S ; Fabbri, G ; Lucci, D ; Fajardo-Moser, M ; Brenner, S ; Hao, D ; Zhang, H ; Liu, J ; Wuhan, B ; Mosegaard, S ; Herrington, W ; Wanner, C ; Angermann, C ; Ertl, G ; Maggioni, A ; Barter, P ; Mihaylova, B ; Mitchel, Y ; Blaustein, R ; Goto, S ; Tobert, J ; DeLucca, P ; Chen, Y ; Chen, Z ; Gray, A ; Haynes, R ; Armitage, J ; Baigent, C ; Wiviott, S ; Cannon, C ; Braunwald, E ; Collins, R ; Bowman, L ; Landray, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-e76e38a99fe8b7ec3545edcfefde661525ebd8decf958ed2e8e1f39025a47e443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Atherosclerosis - drug therapy</topic><topic>Atorvastatin - therapeutic use</topic><topic>Clinical Research</topic><topic>Double-Blind Method</topic><topic>Humans</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Oxazolidinones - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sammons, E</creatorcontrib><creatorcontrib>Hopewell, J C</creatorcontrib><creatorcontrib>Chen, F</creatorcontrib><creatorcontrib>Stevens, W</creatorcontrib><creatorcontrib>Wallendszus, K</creatorcontrib><creatorcontrib>Valdes-Marquez, E</creatorcontrib><creatorcontrib>Dayanandan, R</creatorcontrib><creatorcontrib>Knott, C</creatorcontrib><creatorcontrib>Murphy, K</creatorcontrib><creatorcontrib>Wincott, E</creatorcontrib><creatorcontrib>Baxter, A</creatorcontrib><creatorcontrib>Goodenough, R</creatorcontrib><creatorcontrib>Lay, M</creatorcontrib><creatorcontrib>Hill, M</creatorcontrib><creatorcontrib>Macdonnell, S</creatorcontrib><creatorcontrib>Fabbri, G</creatorcontrib><creatorcontrib>Lucci, D</creatorcontrib><creatorcontrib>Fajardo-Moser, M</creatorcontrib><creatorcontrib>Brenner, S</creatorcontrib><creatorcontrib>Hao, D</creatorcontrib><creatorcontrib>Zhang, H</creatorcontrib><creatorcontrib>Liu, J</creatorcontrib><creatorcontrib>Wuhan, B</creatorcontrib><creatorcontrib>Mosegaard, S</creatorcontrib><creatorcontrib>Herrington, W</creatorcontrib><creatorcontrib>Wanner, C</creatorcontrib><creatorcontrib>Angermann, C</creatorcontrib><creatorcontrib>Ertl, G</creatorcontrib><creatorcontrib>Maggioni, A</creatorcontrib><creatorcontrib>Barter, P</creatorcontrib><creatorcontrib>Mihaylova, B</creatorcontrib><creatorcontrib>Mitchel, Y</creatorcontrib><creatorcontrib>Blaustein, R</creatorcontrib><creatorcontrib>Goto, S</creatorcontrib><creatorcontrib>Tobert, J</creatorcontrib><creatorcontrib>DeLucca, P</creatorcontrib><creatorcontrib>Chen, Y</creatorcontrib><creatorcontrib>Chen, Z</creatorcontrib><creatorcontrib>Gray, A</creatorcontrib><creatorcontrib>Haynes, R</creatorcontrib><creatorcontrib>Armitage, J</creatorcontrib><creatorcontrib>Baigent, C</creatorcontrib><creatorcontrib>Wiviott, S</creatorcontrib><creatorcontrib>Cannon, C</creatorcontrib><creatorcontrib>Braunwald, E</creatorcontrib><creatorcontrib>Collins, R</creatorcontrib><creatorcontrib>Bowman, L</creatorcontrib><creatorcontrib>Landray, M</creatorcontrib><creatorcontrib>HPS3/TIMI55-REVEAL Collaborative Group</creatorcontrib><creatorcontrib>REVEAL Collaborative Group</creatorcontrib><creatorcontrib>Writing Committee</creatorcontrib><creatorcontrib>The HPS3/TIMI55-REVEAL Collaborative Group</creatorcontrib><collection>Access via Oxford University Press (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sammons, E</au><au>Hopewell, J C</au><au>Chen, F</au><au>Stevens, W</au><au>Wallendszus, K</au><au>Valdes-Marquez, E</au><au>Dayanandan, R</au><au>Knott, C</au><au>Murphy, K</au><au>Wincott, E</au><au>Baxter, A</au><au>Goodenough, R</au><au>Lay, M</au><au>Hill, M</au><au>Macdonnell, S</au><au>Fabbri, G</au><au>Lucci, D</au><au>Fajardo-Moser, M</au><au>Brenner, S</au><au>Hao, D</au><au>Zhang, H</au><au>Liu, J</au><au>Wuhan, B</au><au>Mosegaard, S</au><au>Herrington, W</au><au>Wanner, C</au><au>Angermann, C</au><au>Ertl, G</au><au>Maggioni, A</au><au>Barter, P</au><au>Mihaylova, B</au><au>Mitchel, Y</au><au>Blaustein, R</au><au>Goto, S</au><au>Tobert, J</au><au>DeLucca, P</au><au>Chen, Y</au><au>Chen, Z</au><au>Gray, A</au><au>Haynes, R</au><au>Armitage, J</au><au>Baigent, C</au><au>Wiviott, S</au><au>Cannon, C</au><au>Braunwald, E</au><au>Collins, R</au><au>Bowman, L</au><au>Landray, M</au><aucorp>HPS3/TIMI55-REVEAL Collaborative Group</aucorp><aucorp>REVEAL Collaborative Group</aucorp><aucorp>Writing Committee</aucorp><aucorp>The HPS3/TIMI55-REVEAL Collaborative Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2022-04-06</date><risdate>2022</risdate><volume>43</volume><issue>14</issue><spage>1416</spage><epage>1424</epage><pages>1416-1424</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract
Aims
REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment period.
Methods and results
A total of 30 449 adults with prior atherosclerotic vascular disease were randomly allocated to anacetrapib 100 mg daily or matching placebo, in addition to open-label atorvastatin therapy. After stopping the randomly allocated treatment, 26 129 survivors entered a post-trial follow-up period, blind to their original treatment allocation. The primary outcome was first post-randomization major coronary event (i.e. coronary death, myocardial infarction, or coronary revascularization) during the in-trial and post-trial treatment periods, with analysis by intention-to-treat. Allocation to anacetrapib conferred a 9% [95% confidence interval (CI) 3–15%; P = 0.004] proportional reduction in the incidence of major coronary events during the study treatment period (median 4.1 years). During extended follow-up (median 2.2 years), there was a further 20% (95% CI 10–29%; P < 0.001) reduction. Overall, there was a 12% (95% CI 7–17%, P < 0.001) proportional reduction in major coronary events during the overall follow-up period (median 6.3 years), corresponding to a 1.8% (95% CI 1.0–2.6%) absolute reduction. There were no significant effects on non-vascular mortality, site-specific cancer, or other serious adverse events. Morbidity follow-up was obtained for 25 784 (99%) participants.
Conclusion
The beneficial effects of anacetrapib on major coronary events increased with longer follow-up, and no adverse effects emerged on non-vascular mortality or morbidity. These findings illustrate the importance of sufficiently long treatment and follow-up duration in randomized trials of lipid-modifying agents to assess their full benefits and potential harms.
Trial registration
International Standard Randomized Controlled Trial Number (ISRCTN) 48678192; ClinicalTrials.gov No. NCT01252953; EudraCT No. 2010-023467-18.
Structured Graphical Abstract
Structured Graphical Abstract</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>34910136</pmid><doi>10.1093/eurheartj/ehab863</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8647-0366</orcidid><orcidid>https://orcid.org/0000-0001-6646-827X</orcidid><orcidid>https://orcid.org/0000-0001-8288-8602</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2022-04, Vol.43 (14), p.1416-1424 |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8986460 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Adult Atherosclerosis - drug therapy Atorvastatin - therapeutic use Clinical Research Double-Blind Method Humans Myocardial Infarction - drug therapy Oxazolidinones - adverse effects Treatment Outcome |
| title | Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T22%3A54%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20safety%20and%20efficacy%20of%20anacetrapib%20in%20patients%20with%20atherosclerotic%20vascular%20disease&rft.jtitle=European%20heart%20journal&rft.au=Sammons,%20E&rft.aucorp=HPS3/TIMI55-REVEAL%20Collaborative%20Group&rft.date=2022-04-06&rft.volume=43&rft.issue=14&rft.spage=1416&rft.epage=1424&rft.pages=1416-1424&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehab863&rft_dat=%3Coup_pubme%3E10.1093/eurheartj/ehab863%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34910136&rft_oup_id=10.1093/eurheartj/ehab863&rfr_iscdi=true |